IntermediateEvidence: Grade Bsexual wellness

The Sexual Wellness Protocol

A three-layer protocol addressing sexual wellness from the ground up: Zinc builds the hormonal foundation; PT-141 activates central arousal pathways via melanocortin receptors; Oxytocin deepens emotional connection and amplifies the bonding dimension of intimacy. The only evidence-backed supplement stack that addresses both the physiological and psychological dimensions of sexual function simultaneously.

3 steps·3 compounds·Published March 25, 2026

Daily Schedule

Timing and dosage for each step

Daily (evening)

30 mg

30mg Zinc Bisglycinate with dinner - daily foundational supplementation. Optimises testosterone and gonadal function as the hormonal baseline. Start this 2-4 weeks before PT-141 use for best results.

T-60 min (before activity)

1 mg

1mg subcutaneous injection 45-60 minutes before intended sexual activity. Start at 0.5mg on first use to assess nausea tolerance. Do NOT combine with Viagra, Cialis, or any PDE5 inhibitor.

T-15 min (before activity)

OxytocinTier B

40 mcg

20-40 IU intranasal spray (1-2 puffs per nostril) approximately 15-20 minutes before sexual activity. Enhances emotional connection and bonding alongside PT-141's arousal effect.

Protocol Architecture

Most sexual wellness approaches target a single mechanism. This protocol addresses three distinct layers:

Layer 1 — Hormonal Foundation (Zinc, daily) Zinc is the rate-limiting mineral for testosterone synthesis. Deficiency -- extremely common in Western diets -- directly reduces gonadal function, libido, and sexual response in both men and women. Correcting deficiency creates the hormonal environment within which the other compounds operate most effectively. Start zinc supplementation 2-4 weeks before using PT-141 and oxytocin.

Layer 2 — Central Arousal (PT-141, on-demand) PT-141 (Bremelanotide) activates melanocortin receptors (MC3R, MC4R) in the hypothalamus and limbic system -- the neural circuits responsible for generating sexual desire. Unlike PDE5 inhibitors which improve peripheral blood flow without affecting desire, PT-141 creates the neurological state of arousal and motivation. Works in both men and women. The active ingredient in FDA-approved Vyleesi.

Layer 3 — Emotional Connection (Oxytocin, on-demand) Oxytocin enhances bonding, trust, and the emotional quality of intimate experience. It reduces amygdala-mediated social threat responses and increases dopamine release in the reward pathway during intimacy. PT-141 and Oxytocin are complementary: PT-141 generates desire; Oxytocin deepens the connection.

Timing Protocol

Daily (ongoing): Zinc Bisglycinate 30mg with dinner

On the day of use:

  • T-60 min: PT-141 1mg subcutaneous injection
  • T-15 min: Oxytocin 20-40 IU intranasal

PT-141 reaches peak concentration approximately 45-60 minutes after injection and effects persist for 6-12 hours. Do not re-dose within 72 hours.

Critical Safety Note: PT-141 and PDE5 Inhibitors

Do not combine PT-141 with Viagra (Sildenafil), Cialis (Tadalafil), Levitra (Vardenafil), or any PDE5 inhibitor. Both compounds lower blood pressure through different mechanisms, and the combination can cause significant hypotension. This is a formal contraindication on the FDA Vyleesi label.

Nausea Management

Nausea is the most common PT-141 side effect (30-40% of users, typically mild). Strategies to reduce it:

  • Start at 0.5mg for first use, titrate to 1mg if well-tolerated
  • Take 4mg ondansetron (Zofran) 30 minutes before PT-141 injection
  • Maintain light food intake in the 2 hours before administration
  • Stay well hydrated

Who This Protocol Is For

  • Individuals experiencing reduced libido or sexual desire (both men and women)
  • Couples seeking to enhance intimacy and emotional connection
  • Men experiencing psychogenic erectile dysfunction (where desire, not mechanics, is the primary issue)
  • Women with hypoactive sexual desire disorder (HSDD) -- the primary FDA-approved indication for bremelanotide

Research Peptide Notice

PT-141 and Oxytocin in research peptide form are not the FDA-approved pharmaceutical products. For educational purposes only.